Hints and tips:
Related Special Reports
...Although Mitsui Fudosan is the largest Japanese property group by value, it has, at 6.91 per cent, the lowest return on equity among peers such as Mitsubishi Estate and Sumitomo Realty....
...Gilead has worked with scientists at Accelerated Clinical Trials Ltd to develop a blood cancer treatment....
...As healthcare systems around the world put pressure on drug prices, pharma companies are also looking for ways to cut costs in research and development....
...Clinical trials of the first AI-designed molecule — announced in 2020 by Oxford-based Exscientia and Sumitomo Pharma — were unsuccessful....
...Astellas Pharma bought eye-treatment specialist Iveric Bio in a $5.9bn deal in May. Mizuho splashed out $550mn for US boutique investment bank Greenhill & Co....
...In September 2019, Roivant sold five of its most promising subsidiaries to Japan’s Sumitomo Dainippon Pharma in a blockbuster $3bn deal....
...Japanese pharma group Eisai said new analysis found 60 per cent of patients at the very early stages of Alzheimer’s showed a clinical improvement after taking its drug Leqembi for 18 months, compared to...
...The trial scheme, known as “Any Wear, Anywhere”, led by JAL and the trading house Sumitomo, has been pitched as an attempt to promote sustainable tourism....
...The transaction will be funded by a $7bn financing commitment provided by Sumitomo Mitsui Banking Corporation....
Daiichi Sankyo and AstraZeneca’s Enhertu could double time patients can live without their condition progressing
...Amid expectations of booming demand for fever medicine and other drugs, mainland China-listed shares of pharma companies Guangzhou Baiyunshan Pharmaceutical and Hualan Biological Engineering each gained...
...Gilead SciencesO: 6; L: 8; I: 7; Total: 21The South Korean legal team at the US-based pharma group increased self-service on legal issues in the rest of the business....
...The fund manager, a sister company of Japan’s Sumitomo Mitsui Trust Bank, has $572bn under management making it one of the largest fund managers in Asia....
...Kevin Gorman, senior vice-president at German pharma giant Merck, a key supplier to the chip industry, says the company’s scientists have been working on PFAS-free alternatives since 2020....
...“When you watch a horrendously large percentage of your assets disappear out of the door within an extraordinarily short period of time, you vow that you would never allow this to happen,” co-founder Ian...
...As pharma blogger Derek Lowe pointed out, the drug removes plaques but doesn’t slow the disease all that much. Worse, clearing the plaques carries risks....
...“Many of the current working population are very sceptical about prices and wages rising since they have never experienced it,” said Hiroyuki Ueno, chief strategist at Sumitomo Mitsui Trust Asset Management...
...Shares in Biogen and Eisai surged on Wednesday after the pharma groups said they would apply for regulatory approval for a new Alzheimer’s drug following a late-stage clinical trial that showed it slowed...
...The head of pharma company Sanofi said UK economic policy meant the country was falling behind in healthcare innovation....
...He used to be the chief of French pharma giant Sanofi. Millennium Management, the multi-strategy hedge fund, has hired Justin Gmelich from King Street as its new co-chief investment officer....
...Nissan model], including its batteries, are exported abroad as used cars and there are fewer vehicles left in Japan,” said Yutaka Horie, president of 4R Energy, Nissan’s joint venture with trading house Sumitomo...
...International co-operation is desperately needed to solve this market failure....
...Under a three-year business plan unveiled last month, the company will invest ¥100bn in research and development or to expand factories in the health science and pharma sectors, and ¥80bn in its beer and...
...Tara Hansen, a consultant at Informa Pharma Custom Intelligence, said the trial results were “groundbreaking” and would position Enhertu as a competitive option in a patient population with a high unmet...
...The company already has drug candidates in clinical trials, two psychiatric treatments in partnership with Japanese drugmaker Sumitomo Dainippon Pharma, and another in oncology, which it is developing itself...
International Edition